ClinicalTrials.gg
RecruitingNCT07335601Updated Aug 26, 2026

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

A Phase 2 interventional study of Resmetirom and Placebo in MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 415 studies in Fibrosis with a site in United States — 81 open to participants now, 109 under way, 13 of them phase 3. Fibrosis · United States.

Planned enrollment
96th of 330
120 · median 52
Started
2025
with 18 others
Phase 2
98 of 415
20 open now
Primary completion
2028-08
later than 70 of 108 live
Registered
396th of 415
by date

Among the 415 studies in Fibrosis with a site in United States, this one is the 96th largest by planned enrollment of the 330 interventional ones that give a count, is one of 19 that started in 2025, is one of 98 in phase 2, reaches primary completion later than 70 of the 108 other live ones, and was the 396th registered.

Fibrosis

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

Browse Fibrosis studies →

Open to participants now

81 of the 415 studies in Fibrosis with a site in United States are open now. Recruiting first, the newest first:

75 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Fibrosis with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.

03

Conditions studied

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

Keywords

  • Post-Liver Transplant
  • Cirrhosis
  • Metabolic dysfunction-associated steatohepatitis (MASH)
  • MASLD
  • MASH
  • Liver
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 12 months post-liver transplant at screening and meeting one of the following:

    • Cohort 1: Liver transplant for MASH cirrhosis with recurrent hepatic steatosis ≥8% by MRI-PDFF
    • Cohort 2: Liver transplant for non-MASH etiology with de novo hepatic steatosis ≥8% by MRI-PDFF
  2. Presence of at least one metabolic risk factor, including overweight/obesity, dysglycemia or type 2 diabetes, hypertension or antihypertensive treatment, hypertriglyceridemia or low HDL cholesterol, or lipid-lowering therapy.
  3. MASH with moderate to advanced liver fibrosis (F2-F3), confirmed by noninvasive fibrosis assessment (FibroScan and/or MRE) and a liver consistent with Stage F2/F3 MASH and no evidence of other liver pathology or graft rejection.
  4. Stable renal function with estimated (eGFR) ≥30 mL/min/1.73 m² prior to and during screening.
  5. Stable liver enzymes at screening, without worsening compared with recent historical values.
  6. Stable regimen for at least 3 months prior to screening.
  7. Females of must have a negative pregnancy test, not be breastfeeding, and agree to use effective during the study and for at least 30 days after the last dose; females not of childbearing potential are eligible.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another interventional clinical trial with drug exposure within 30 days (or 5 half-lives, whichever is longer) prior to screening.
  2. Phosphatidylethanol (PEth) value of ≥20 ng/mL measured at screening or alcohol use within 1 year prior to screening.
  3. FibroScan VCTE >20 kPa, a baseline demonstrating fibrosis consistent with F4, or MRE > 5 kPa.
  4. Uncontrolled or clinically significant thyroid disease, including active hyperthyroidism or untreated hypothyroidism.
  5. Evidence of active liver disease other than MASH.
  6. History of liver transplantation for an inborn error of metabolism.
  7. Evidence of hepatic impairment or decompensation at screening.
  8. resistant rejection of the transplanted liver or kidney, or a history of a rejection treated with high dose steroid within 3 months of screening.
  9. Chronic rejection or chronic plasma-cell hepatitis.
  10. Significant post-transplant vascular or biliary complications.
  11. Significant cardiovascular or cerebrovascular disease within 6 months prior to randomization.
  12. Uncontrolled hypertension at screening or randomization.
  13. Current hepatocellular carcinoma.
  14. Known (HIV) infection or other clinically significant state.
  15. Any serious medical condition with a of less than 5 years.
  16. Current substance abuse or drug addiction.
  17. Significant psychiatric, cognitive, or social conditions that would interfere with study participation or compliance, in the Investigator's judgment.
  18. Known to study drug or any of its .
  19. Use of prohibited concomitant medications that may affect liver function, steatosis, thyroid function, or study outcomes, or unstable doses of allowed metabolic therapies prior to randomization.
  20. Use of statins above protocol-allowed doses or unstable lipid-lowering therapy prior to randomization.
  21. to MRI, including implanted devices incompatible with MRI, severe claustrophobia, or inability to undergo MRI procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Resmetirom 80 or 100 mg daily - Cohort 1

    Drug: Resmetirom

  • Active comparator
    Arm 2: Resmetirom 80 or 100 mg daily - Cohort 2

    Drug: Resmetirom

  • Placebo comparator
    Arm 3: Placebo - Cohort 1

    Drug: Placebo

  • Placebo comparator
    Arm 4: Placebo - Cohort 2

    Drug: Placebo

Interventions

  • Randomized 80 or 100 mg

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28

    To determine the effect of MGL-3196/Resmetirom versus matching placebo on percent change from Baseline to Week 28 in hepatic fat fraction by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in patients with baseline MRI-PDFF ≥8%.

    Time frame: 28 weeks

Secondary outcomes

  1. To evaluate the safety and tolerability of once-daily, oral administration of MGL-3196/resmetirom versus matching placebo in patients who have undergone a liver transplant

    Time frame: 52 weeks

  2. 1.To determine the effect of MGL-3196/resmetirom versus matching placebo on liver stiffness as measured by FibroScan vibration controlled transient elastography (VCTE; kPa)

    Absolute change and percent change from Baseline to Week 28 and Week 52 on FibroScan VCTE

    Time frame: 28 and 52 Weeks

  3. 2. To determine the effect of MGL-3196/resmetirom versus matching placebo on serum lipid parameters

    Absolute and percent change from Baseline to Week 28 and Week 52 in LDL-C, lipoprotein A \[Lp(a)\] in patients with baseline Lp(a) \>10 nmol/L and triglycerides (TGs) in patients with baseline TGs \>150 mg/dL

    Time frame: 28 and 52 Weeks

  4. 3. To determine the effect of MGL-3196/resmetirom versus matching placebo on liver biochemistries

    Absolute and percent change from baseline in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT), at Week 28 and Week 52

    Time frame: 28 and 52 weeks

07

Study locations

12 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2028, 32 months after the start.

Of 42 industry-sponsored phase 2 interventional studies under Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 36. This study's planned 32 months is above that.

Counting every sponsor, half of 71 studies reached it within 36 months; a quarter within 19 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 13, 2026
StartActual
Dec 29, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Mar 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335601
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Dec 29, 2025
Primary completion
Aug 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

David Hernandez, MD
Contact
dhernandez@madrigalpharma.com
302-640-2217
Tom Hare, MS
study director · Madrigal Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion